Michael J Koren
Overview
Explore the profile of Michael J Koren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
3248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
Koren M, Rodriguez F, East C, Toth P, Watwe V, Abbas C, et al.
J Am Coll Cardiol
. 2024 Apr;
83(20):1939-1952.
PMID: 38593947
Background: Most patients with atherosclerotic cardiovascular disease fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals. Twice-yearly inclisiran lowers LDL-C by ∼50% when added to statins. Objectives: This study evaluated...
2.
Nissen S, Wolski K, Watts G, Koren M, Fok H, Nicholls S, et al.
JAMA
. 2024 Apr;
331(18):1534-1543.
PMID: 38587822
Importance: Lipoprotein(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis, with no pharmacological treatments approved by regulatory authorities. Objectives: To assess the safety and...
3.
Koren M, Descamps O, Hata Y, Hengeveld E, Hovingh G, Ikonomidis I, et al.
Lancet Diabetes Endocrinol
. 2024 Feb;
12(3):174-183.
PMID: 38310920
Background: Currently available injectable drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular outcomes. This phase 2 study assessed NNC0385-0434, an oral PCSK9...
4.
Vavere A, Sinsakul M, Ongstad E, Yang Y, Varma V, Jones C, et al.
J Am Heart Assoc
. 2023 Jan;
12(3):e027540.
PMID: 36688371
Background Blockade of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a potentially attractive mechanism for lowering inflammatory and lipid risk in patients with atherosclerosis. This study aims to assess...
5.
Kallend D, Mason J, Smith P, Koren M, Stoekenbroek R, He Y, et al.
Clin Transl Sci
. 2022 Oct;
15(11):2663-2672.
PMID: 36196601
Inclisiran is a small interfering RNA molecule that has been shown to provide an effective and sustained reduction in low-density lipoprotein cholesterol levels. This study aimed to determine whether a...
6.
Schludi B, Giugliano R, Sabatine M, Raal F, Teramoto T, Koren M, et al.
J Clin Lipidol
. 2022 Jun;
16(4):538-543.
PMID: 35760720
LDL-C is the pivotal risk factor for atherosclerotic cardiovascular disease, and the benefit from LDL-C lowering is proportional to the magnitude of reduction. Clinical trials demonstrate that evolocumab reduces LDL-C...
7.
Winkle P, Goldsmith S, Koren M, Lepage S, Hellawell J, Trivedi A, et al.
Cardiovasc Drugs Ther
. 2022 Apr;
37(4):743-755.
PMID: 35460392
Purpose: AMG 986 is a novel apelin receptor (APJ) agonist that improves cardiac contractility in animal models without adversely impacting hemodynamics. This phase 1b study evaluated the safety/tolerability, pharmacokinetics, and...
8.
Moreira Jr E, Kitchin N, Xu X, Dychter S, Lockhart S, Gurtman A, et al.
N Engl J Med
. 2022 Mar;
386(20):1910-1921.
PMID: 35320659
Background: Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic....
9.
Hulton S, Groothoff J, Frishberg Y, Koren M, Overcash J, Sellier-Leclerc A, et al.
Kidney Int Rep
. 2022 Mar;
7(3):494-506.
PMID: 35257062
Introduction: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. In the 6-month...
10.
Koren M, Moriarty P, Baum S, Neutel J, Hernandez-Illas M, Weintraub H, et al.
Nat Med
. 2022 Jan;
28(1):96-103.
PMID: 35027752
Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. Here we report the discovery and development...